Zensun   Report issue

For profit Phase 2 Phase 3
Founded: Shanghai China (2000)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2010
NCT01131637
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Zensun Sci. & Tech. Co., Ltd. | Zensun USA Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

neuregulin (8 trials)

Drugs in Phase 2 Trials (1)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 3)

Heart Failure, Systolic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 2